‘In China For Global’ Approach Fuels Chinese Biotech Forays
Executive Summary
China's emerging role as a launch pad for global biotech ventures is slowly taking shape, fueled by ready venture capital funding and strong government support. Although capital outflow controls are tightening, the number of biotech deals will ratchet up, executives say.
You may also be interested in...
What's Driving The Uptick In Korea-China Biotech Deals
Bilateral ties between South Korea and China may have slumped to a new low, but that doesn’t seem to have deterred deals between firms in the two nations in the biotech space. Scrip takes a closer look at the deal-making flow and whether it is sustainable.
China Investment Roundup: Strategic Overseas Moves Target Product Acquisitions
R&D-based big pharma groups in China with sufficient cash flow are increasing their strategic investments in overseas companies and products with an eye on entry to the global market, while start-ups continue to actively raise new funds from venture capitalists.
Innovation The Big Winner As China Joins ICH
Patients, international companies, and innovation-driven firms are set to gain the most from China’s dramatic move to join the ICH process, says one regulatory affairs veteran.